Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

What is next, and who is running it?

Programs by company or class, across phase, filing, approval, and a stop.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Phase 1 on
ClassNone selected

Phase 1 included.

Clear filters

15 of 15 programs on this matrix

Phase 1Phase 2Phase 3FiledApprovedDiscontinued
Alliance1 program
ECOG-ACRIN1 program
GEINO1 program
Tuvusertib

Registry, Sep 2028

Dosing n/r

ATR inhibitor (ATRX-altered) · GEINO

German Cancer Research Center1 program
Hospices Civils de Lyon (OLAGLI)1 program
Olaparib

Registry, Jan 2027

twice daily, oral

PARP inhibitor · Hospices Civils de Lyon (OLAGLI)

Hutchmed1 program
Massachusetts General Hospital2 programs
Niraparib

Phase 1

Dosing n/r

PARP inhibitor · Massachusetts General Hospital

National Cancer Institute1 program
Nivolumab

Phase 2

Dosing n/r

PD-1 antibody · National Cancer Institute

Nuvation Bio1 program
Rigel1 program
Servier2 programs
Ivosidenib

Phase 1

once daily, oral

mutant IDH1 inhibitor · Servier

Vorasidenib

SNO 2026: INDIGO 41.6-month, seizure/QoL, real-world grade 2 and 3, Nov 12, 2026

once daily, oral

mutant IDH1/IDH2 inhibitor · Servier

University of California, San Francisco1 program
University of Pennsylvania (Stephen Bagley)1 program